Latest News and Press Releases

Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...

Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that...

Data provides further evidence that GoCAR-T® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received...

HOUSTON, May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

HOUSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...

HOUSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

HOUSTON, March 12, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

HOUSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...